Dymon Asia Capital Singapore PTE. LTD. Makes New Investment in Cogent Biosciences, Inc. $COGT

Dymon Asia Capital Singapore PTE. LTD. acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 24,200 shares of the technology company’s stock, valued at approximately $860,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its holdings in Cogent Biosciences by 1,164.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after purchasing an additional 652 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Cogent Biosciences by 41.4% in the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock valued at $33,000 after acquiring an additional 1,333 shares in the last quarter. Strs Ohio bought a new position in shares of Cogent Biosciences in the first quarter valued at approximately $36,000. Global Retirement Partners LLC bought a new position in shares of Cogent Biosciences in the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Cogent Biosciences by 414.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock valued at $46,000 after acquiring an additional 1,032 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on COGT shares. Jefferies Financial Group started coverage on Cogent Biosciences in a report on Monday, March 16th. They issued a “buy” rating and a $55.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Cogent Biosciences in a report on Friday, May 29th. Piper Sandler upped their target price on Cogent Biosciences from $39.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. HC Wainwright upped their target price on Cogent Biosciences to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Robert W. Baird set a $35.00 target price on Cogent Biosciences in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cogent Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.73.

Cogent Biosciences Stock Performance

COGT stock opened at $33.10 on Friday. The business has a 50 day moving average of $34.62 and a 200-day moving average of $36.58. Cogent Biosciences, Inc. has a 12-month low of $6.88 and a 12-month high of $43.73. The firm has a market cap of $5.66 billion, a PE ratio of -15.25 and a beta of 0.34. The company has a quick ratio of 15.14, a current ratio of 15.14 and a debt-to-equity ratio of 0.41.

Cogent Biosciences (NASDAQ:COGT) last released its earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). As a group, sell-side analysts expect that Cogent Biosciences, Inc. will post -2.26 earnings per share for the current year.

Cogent Biosciences Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.